Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.

PubWeight™: 4.55‹?› | Rank: Top 1%

🔗 View Article (PMID 28514601)

Published in N Engl J Med on May 17, 2017

Authors

Michael E Wechsler1, Praveen Akuthota1, David Jayne1, Paneez Khoury1, Amy Klion1, Carol A Langford1, Peter A Merkel1, Frank Moosig1, Ulrich Specks1, Maria C Cid1, Raashid Luqmani1, Judith Brown1, Stephen Mallett1, Richard Philipson1, Steve W Yancey1, Jonathan Steinfeld1, Peter F Weller1, Gerald J Gleich1, EGPA Mepolizumab Study Team

Author Affiliations

1: From the Department of Medicine, National Jewish Health, Denver (M.E.W.); the Division of Pulmonary, Critical Care, and Sleep Medicine, University of California San Diego, La Jolla (P.A.); Beth Israel Deaconess Medical Center, Boston (P.A., P.F.W.); the Department of Medicine, University of Cambridge, Cambridge (D.J.), the Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford (R.L.), Research and Development, Immuno-Inflammation Therapy Area Unit (J.B.), and Research and Development, Statistics, Programming, and Data Standards (S.M.), GlaxoSmithKline, Uxbridge, and Trizell, Oxford (R.P.) - all in the United Kingdom; the Human Eosinophil Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD (P.K., A.K.); the Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland (C.A.L.); the Division of Rheumatology and the Department of Biostatistics and Clinical Epidemiology, University of Pennsylvania (P.A.M.), and the Respiratory Therapy Area Unit and Flexible Discovery Unit, GlaxoSmithKline (J.S.), Philadelphia; Rheumazentrum, Schleswig-Holstein Mitte, Neumünster, Germany (F.M.); the Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN (U.S.); the Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clinic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona (M.C.C.); the Respiratory Therapeutic Area, GlaxoSmithKline, Research Triangle Park, NC (S.W.Y.); and the Departments of Dermatology and Medicine, University of Utah School of Medicine, Salt Lake City (G.J.G.).

Associated clinical trials:

A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis | NCT02020889

Articles cited by this

2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum (2013) 11.18

Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol (1951) 10.58

Development and validation of a questionnaire to measure asthma control. Eur Respir J (1999) 9.35

Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med (2009) 8.36

Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med (2008) 5.94

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med (2009) 5.90

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet (2012) 5.82

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med (2014) 4.95

Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med (2014) 3.50

Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) (1999) 3.50

EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis (2006) 2.35

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum (2013) 2.28

Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis (2008) 2.12

Asthma outcomes: composite scores of asthma control. J Allergy Clin Immunol (2012) 1.85

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med (2015) 1.80

Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. Rheumatology (Oxford) (2014) 1.62

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis (2016) 1.44

Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum (2008) 1.43

Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin Ther (2011) 1.28

Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol (2010) 1.27

Clinical manifestations and treatment of Churg-Strauss syndrome. Rheum Dis Clin North Am (2010) 1.26

Eosinophils in vasculitis: characteristics and roles in pathogenesis. Nat Rev Rheumatol (2014) 1.24

Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med (2011) 1.22

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): evolutions in classification, etiopathogenesis, assessment and management. Curr Opin Rheumatol (2014) 1.16

Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. J Autoimmun (2013) 1.15

Eosinophils and disease pathogenesis. Semin Hematol (2012) 1.05

Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis (2014) 1.01

Churg-strauss syndrome: clinical symptoms, complementary investigations, prognosis and outcome, and treatment. Semin Respir Crit Care Med (2011) 1.00

Sustained response to mepolizumab in refractory Churg-Strauss syndrome. J Allergy Clin Immunol (2010) 1.00

Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome. Ann N Y Acad Sci (2005) 0.99

Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis (2016) 0.97

Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss). PLoS One (2015) 0.89

Patient-reported outcomes in ANCA-associated vasculitis. A comparison between Birmingham Vasculitis Activity Score and routine assessment of patient index data 3. Clin Rheumatol (2015) 0.89

Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Eur Respir J (2016) 0.86